1
|
Kim JW, Choi J, Park MN, Kim B. Apoptotic Effect of Gallic Acid via Regulation of p-p38 and ER Stress in PANC-1 and MIA PaCa-2 Cells Pancreatic Cancer Cells. Int J Mol Sci 2023; 24:15236. [PMID: 37894916 PMCID: PMC10607041 DOI: 10.3390/ijms242015236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 10/11/2023] [Accepted: 10/13/2023] [Indexed: 10/29/2023] Open
Abstract
Pancreatic cancer (PC) is currently recognized as the seventh most prevalent cause of cancer-related mortality among individuals of both genders. It is projected that a significant number of individuals will succumb to this disease in the forthcoming years. Extensive research and validation have been conducted on both gemcitabine and 5-fluorouracil as viable therapeutic options for PC. Nevertheless, despite concerted attempts to enhance treatment outcomes, PC continues to pose significant challenges in terms of achieving effective treatment alone through chemotherapy. Gallic acid, an endogenous chemical present in various botanical preparations, has attracted considerable attention due to its potential as an anticancer agent. The results of the study demonstrated that gallic acid exerted a decline in cell viability that was dependent on its concentration. Furthermore, it efficiently suppressed cell proliferation in PC cells. This study observed a positive correlation between gallic acid and the production of reactive oxygen species (ROS). Additionally, it confirmed the upregulation of proteins associated with the protein kinase-like endoplasmic reticulum kinase (PERK) pathway, which is one of the pathways involved in endoplasmic reticulum (ER) stress. Moreover, the administration of gallic acid resulted in verified alterations in the transmission of mitogen-activated protein kinase (MAPK) signals. Notably, an elevation in the levels of p-p38, which represents the phosphorylated state of p38 MAPK was detected. The scavenger of reactive oxygen species (ROS), N-Acetyl-L-cysteine (NAC), has shown inhibitory effects on phosphorylated p38 (p-p38), whereas the p38 inhibitor SB203580 inhibited C/EBP homologous protein (CHOP). In both instances, the levels of PARP have been successfully reinstated. In other words, the study discovered a correlation between endoplasmic reticulum stress and the p38 signaling pathway. Consequently, gallic acid induces the activation of both the p38 pathway and the ER stress pathway through the generation of ROS, ultimately resulting in apoptosis. The outcomes of this study provide compelling evidence to support the notion that gallic acid possesses considerable promise as a viable therapeutic intervention for pancreatic cancer.
Collapse
Affiliation(s)
- Jeong Woo Kim
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul 05253, Republic of Korea; (J.W.K.); (J.C.); (M.N.P.)
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul 05253, Republic of Korea
| | - Jinwon Choi
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul 05253, Republic of Korea; (J.W.K.); (J.C.); (M.N.P.)
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul 05253, Republic of Korea
| | - Moon Nyeo Park
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul 05253, Republic of Korea; (J.W.K.); (J.C.); (M.N.P.)
| | - Bonglee Kim
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul 05253, Republic of Korea; (J.W.K.); (J.C.); (M.N.P.)
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul 05253, Republic of Korea
| |
Collapse
|
2
|
Gonçalves DA, Jasiulionis MG, de Melo FHM. The Role of the BH4 Cofactor in Nitric Oxide Synthase Activity and Cancer Progression: Two Sides of the Same Coin. Int J Mol Sci 2021; 22:9546. [PMID: 34502450 PMCID: PMC8431490 DOI: 10.3390/ijms22179546] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 08/22/2021] [Accepted: 08/23/2021] [Indexed: 12/14/2022] Open
Abstract
Cancer development is associated with abnormal proliferation, genetic instability, cell death resistance, metabolic reprogramming, immunity evasion, and metastasis. These alterations are triggered by genetic and epigenetic alterations in genes that control cell homeostasis. Increased reactive oxygen and nitrogen species (ROS, RNS) induced by different enzymes and reactions with distinct molecules contribute to malignant transformation and tumor progression by modifying DNA, proteins, and lipids, altering their activities. Nitric oxide synthase plays a central role in oncogenic signaling modulation and redox landscape. Overexpression of the three NOS isoforms has been found in innumerous types of cancer contributing to tumor growth and development. Although the main function of NOS is the production of nitric oxide (NO), it can be a source of ROS in some pathological conditions. Decreased tetrahydrobiopterin (BH4) cofactor availability is involved in NOS dysfunction, leading to ROS production and reduced levels of NO. The regulation of NOSs by BH4 in cancer is controversial since BH4 has been reported as a pro-tumoral or an antitumoral molecule. Therefore, in this review, the role of BH4 in the control of NOS activity and its involvement in the capabilities acquired along tumor progression of different cancers was described.
Collapse
Affiliation(s)
- Diego Assis Gonçalves
- Micro-Imuno-Parasitology Department, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil;
- Department of Parasitology, Microbiology and Immunology, Federal University of Juiz de Fora, Juiz de Fora 36036-900, Brazil
| | | | - Fabiana Henriques Machado de Melo
- Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo 05508-000, Brazil
- Institute of Medical Assistance to Public Servants of the State (IAMSPE), São Paulo 04039-000, Brazil
| |
Collapse
|
3
|
The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors. Antioxidants (Basel) 2020; 9:antiox9050374. [PMID: 32365852 PMCID: PMC7278755 DOI: 10.3390/antiox9050374] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 04/24/2020] [Accepted: 04/27/2020] [Indexed: 02/08/2023] Open
Abstract
Disturbed redox homeostasis represents a hallmark of cancer phenotypes, affecting cellular metabolism and redox signaling. Since reactive oxygen and nitrogen species (ROS/RNS) are involved in regulation of proliferation and apoptosis, they may play a double-faced role in cancer, entailing protumorigenic and tumor-suppressing effects in early and later stages, respectively. In addition, ROS and RNS impact the activity and communication of all tumor constituents, mediating their reprogramming from anti- to protumorigenic phenotypes, and vice versa. An important role in this dichotomic action is played by the variable amounts of O2 in the tumor microenvironment, which dictates the ultimate outcome of the influence of ROS/RNS on carcinogenesis. Moreover, ROS/RNS levels remarkably influence the cancer response to therapy. The relevance of ROS/RNS signaling in solid tumors is witnessed by the emergence of novel targeted treatments of solid tumors with compounds that target ROS/RNS action and production, such as tyrosine kinase inhibitors and monoclonal antibodies, which might contribute to the complexity of redox regulation in cancer. Prospectively, the dual role of ROS/RNS in the different stages of tumorigenesis through different impact on oxidation and nitrosylation may also allow development of tailored diagnostic and therapeutic approaches.
Collapse
|
4
|
Mangano K, Lanteri R, Basile MS, Bellavia N, Latino R, Messina D, Fagone P, Colletti G, Nania R, Caltabiano R, Di Marco R, Di Cataldo A. Effects of GIT-27NO, a NO-donating compound, on hepatic ischemia/reperfusion injury. Int J Immunopathol Pharmacol 2020; 33:2058738419862736. [PMID: 31298048 PMCID: PMC6628530 DOI: 10.1177/2058738419862736] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Hepatic ischemia/reperfusion injury (IRI) is a clinical condition that may lead
to cellular injury and organ dysfunction that can be observed in different
conditions, such as trauma, shock, liver resection, and transplantation.
Moderate levels of nitric oxide (NO) produced by the endothelial isoform of the
NO synthase protect against liver IRI. GIT-27NO is a NO-derivative of the
toll-like receptor 4 antagonist VGX-1027 that has been shown to possess both
antineoplastic and immunomodulatory properties in vitro and in vivo. In this
study, we have investigated the effects of this compound in vitro, in a model of
oxidative stress induced in HepG2 cells by hydrogen peroxide
(H2O2), and in vivo, in a rat model of IRI of the
liver. GIT-27NO significantly counteracted the toxic effects induced by the
H2O2 on the HepG2 cells and in vivo, GIT-27NO reduced
the transaminase levels and the histological liver injury by reducing necrotic
areas with preservation of viable tissue. These effects were almost similar to
that of the positive control drug dimethyl fumarate. These data suggest that the
beneficial effect of GIT-27NO in the hepatic IRI can be secondary to
anti-oxidative effects and hepatocyte necrosis reduction probably mediated by NO
release.
Collapse
Affiliation(s)
- Katia Mangano
- 1 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Raffaele Lanteri
- 2 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| | - Maria Sofia Basile
- 1 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Noemi Bellavia
- 2 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| | - Rosalia Latino
- 2 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| | - Domenico Messina
- 1 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Paolo Fagone
- 1 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Giuseppe Colletti
- 1 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Riccardo Nania
- 1 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Rosario Caltabiano
- 3 Department of Surgical Sciences, Organ Transplantation and Advanced Technologies, G.F. Ingrassia, University of Catania, Catania, Italy
| | - Roberto Di Marco
- 4 Department of Medicine and Health Sciences "Vincenzo Tiberio," University of Molise, Campobasso, Italy
| | - Antonio Di Cataldo
- 2 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| |
Collapse
|
5
|
Hou L, Zhang Y, Yang X, Tian C, Yan Y, Zhang H, Shi J, Zhang H, Zhang Z. Intracellular NO-Generator Based on Enzyme Trigger for Localized Tumor-Cytoplasm Rapid Drug Release and Synergetic Cancer Therapy. ACS APPLIED MATERIALS & INTERFACES 2019; 11:255-268. [PMID: 30561993 DOI: 10.1021/acsami.8b17750] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Nitric oxide (NO) is an important biological messenger implicated in tumor therapy. However, current NO release systems suffer from some disadvantages, such as hydrolysis during blood circulation, poor specificity, and robust irradiation for stimuli. Accordingly, we constructed an intracellular enzyme-triggered NO-generator to achieve tumor cytoplasm-specific disruption and localized rapid drug release. Diethylamine NONOate (DEA/NO) was used as a NO donor and conjugated with hyaluronic acid (HA) to form self-assembly micelle (HA-DNB-DEA/NO), and encapsulate chemotherapeutic agent (doxorubicin (DOX)) into its hydrophobic core (DOX@HA-DNB-DEA/NO). After HA receptor mediated internalization into tumor cells, HA shell would undergo digestion into small conjugated pieces by hyaluronidase. Meanwhile, DOX@HA-DNB-DEA/NO also responded to the intratumoral overexpressed glutathion and glutathione S-transferase π, leading to the intracellular NO production and controlled DOX rapid release. In vitro and in vivo results proved the enzyme-dependent and enhanced targeting delivery profile, and demonstrated that NO and DOX could colocate in specific tumor site, which provided a precondition for exerting their synergistic efficacy. Moreover, expression of p53 protein was upregulated in tumor tissue after treatment, indicating that NO induced cell apoptosis mediated by tumor suppressor gene p53. Overall, this intelligent drug loaded NO-generator might perform as an enhancer to realize better clinical outcomes.
Collapse
Affiliation(s)
- Lin Hou
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Henan Province , Zhengzhou , China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation , Henan Province , Zhengzhou , China
| | - Yinling Zhang
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Modern Analysis and Computer Center of Zhengzhou University , Henan Province , Zhengzhou , China
| | - Xuemei Yang
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Modern Analysis and Computer Center of Zhengzhou University , Henan Province , Zhengzhou , China
| | - Chunyu Tian
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Modern Analysis and Computer Center of Zhengzhou University , Henan Province , Zhengzhou , China
| | - Yingshan Yan
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Modern Analysis and Computer Center of Zhengzhou University , Henan Province , Zhengzhou , China
| | - Hongling Zhang
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Henan Province , Zhengzhou , China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation , Henan Province , Zhengzhou , China
| | - Jinjin Shi
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Henan Province , Zhengzhou , China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation , Henan Province , Zhengzhou , China
| | - Huijuan Zhang
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Henan Province , Zhengzhou , China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation , Henan Province , Zhengzhou , China
| | - Zhenzhong Zhang
- School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , China
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Henan Province , Zhengzhou , China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation , Henan Province , Zhengzhou , China
| |
Collapse
|
6
|
Abstract
The increasing understanding of the role of nitric oxide (NO) in cancer biology has generated significant progress in the use of NO donor-based therapy to fight cancer. These advances strongly suggest the potential adoption of NO donor-based therapy in clinical practice, and this has been supported by several clinical studies in the past decade. In this review, we first highlight several types of important NO donors, including recently developed NO donors bearing a dinitroazetidine skeleton, represented by RRx-001, with potential utility in cancer therapy. Special emphasis is then given to the combination of NO donor(s) with other therapies to achieve synergy and to the hybridization of NO donor(s) with an anticancer drug/agent/fragment to enhance the activity or specificity or to reduce toxicity. In addition, we briefly describe inducible NO synthase gene therapy and nanotechnology, which have recently entered the field of NO donor therapy.
Collapse
Affiliation(s)
- Zhangjian Huang
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , Nanjing 210009, P. R. China
| | - Junjie Fu
- Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University , Nanjing 211166, P.R. China
| | - Yihua Zhang
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , Nanjing 210009, P. R. China
| |
Collapse
|
7
|
RUSSO ANGELA, FICILI BARTOLOMEA, CANDIDO SAVERIO, PEZZINO FRANCAMARIA, GUARNERI CLAUDIO, BIONDI ANTONIO, TRAVALI SALVATORE, McCUBREY JAMESA, SPANDIDOS DEMETRIOSA, LIBRA MASSIMO. Emerging targeted therapies for melanoma treatment (review). Int J Oncol 2014; 45:516-24. [PMID: 24899250 PMCID: PMC4091965 DOI: 10.3892/ijo.2014.2481] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 06/03/2014] [Indexed: 12/14/2022] Open
Abstract
Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease. The identification of several key molecular pathways implicated in the pathogenesis of melanoma has led to the development of novel therapies for this devastating disease. In melanoma, both the Ras/Raf/MEK/ERK (MAPK) and the PI3K/AKT (AKT) signalling pathways are constitutively activated through multiple mechanisms. Targeting various effectors of these pathways with pharmacologic inhibitors may inhibit melanoma cell growth and angiogenesis. Ongoing clinical trials provide hope to improve progression-free survival of patients with advanced melanoma. This review summarizes the most relevant studies focused on the specific action of these new molecular targeted agents. Mechanisms of resistance to therapy are also discussed.
Collapse
Affiliation(s)
- ANGELA RUSSO
- Laboratory of Translational Oncology and Functional Genomics, Section of General Pathology and Oncology, Department of Biomedical Sciences, University of Catania, I-95124 Catania, Italy
| | - BARTOLOMEA FICILI
- Laboratory of Translational Oncology and Functional Genomics, Section of General Pathology and Oncology, Department of Biomedical Sciences, University of Catania, I-95124 Catania, Italy
| | - SAVERIO CANDIDO
- Laboratory of Translational Oncology and Functional Genomics, Section of General Pathology and Oncology, Department of Biomedical Sciences, University of Catania, I-95124 Catania, Italy
| | - FRANCA MARIA PEZZINO
- Laboratory of Translational Oncology and Functional Genomics, Section of General Pathology and Oncology, Department of Biomedical Sciences, University of Catania, I-95124 Catania, Italy
| | - CLAUDIO GUARNERI
- Department of Social Territorial Medicine, Section of Dermatology, University of Messina, I-98125 Messina, Italy
| | - ANTONIO BIONDI
- Department of Surgery, University of Catania, I-95124 Catania, Italy
| | - SALVATORE TRAVALI
- Laboratory of Translational Oncology and Functional Genomics, Section of General Pathology and Oncology, Department of Biomedical Sciences, University of Catania, I-95124 Catania, Italy
| | - JAMES A. McCUBREY
- Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA
| | - DEMETRIOS A. SPANDIDOS
- Department of Virology, Medical School, University of Crete, Heraklion 71003, Crete, Greece
| | - MASSIMO LIBRA
- Laboratory of Translational Oncology and Functional Genomics, Section of General Pathology and Oncology, Department of Biomedical Sciences, University of Catania, I-95124 Catania, Italy
| |
Collapse
|
8
|
Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, Libra M, McCubrey JA, Nicoletti F. Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol 2012; 112:63-9. [PMID: 22762560 DOI: 10.1111/j.1742-7843.2012.00923.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2012] [Accepted: 06/27/2012] [Indexed: 12/19/2022]
Abstract
Rapamycin is a macrocyclic lactone currently used for the treatment of cancer and for the prevention of transplant rejection. The primary pharmacological mode of action of rapamycin occurs through the inhibition (blocking) of the mammalian target of rapamycin (mTOR). By doing so, rapamycin interferes with the phosphoinositide 3-kinase (PI3K)-Akt-mTOR axis that controls several cellular functions involving cell growth, proliferation and angiogenesis. The frequent activation of the phosphoinositide 3-kinase (PI3K)/AKT pathway in advanced prostate cancer has provided a rationale for the use of mTOR inhibitors in this setting. We carried out a comparative study on the effects of rapamycin and temsirolimus on the in vitro and in vivo growth of the prostate cancer cell lines, LnCap and PC3. Our results demonstrate that rapamycin and temsirolimus exert similar in vitro and in vivo anti-proliferative effects against prostate cancer cells.
Collapse
Affiliation(s)
- Paolo Fagone
- Department of Bio-Medical Sciences, School of Medicine, University of Catania, 95124 Catania, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Bourouba M, Boukercha A, Zergoun AA, Zebboudj A, Elhadjan M, Djenaoui D, Asselah F, Touil-Boukoffa C. Increased production of nitric oxide correlates with tumor growth in Algerian patients with nasopharyngeal carcinoma. Biomarkers 2012; 17:618-24. [PMID: 22817561 DOI: 10.3109/1354750x.2012.706643] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Nasopharyngeal carcinoma (NPC) is thought to arise because of chronic inflammation. The correlation between nitric oxide (NO) production, a biomarker of inflammation and NPC development remains unexplored. To investigate this question, we performed a profile analysis on plasma collected from untreated, treated, remissive, cured and relapsing patients. Nitrites were measured to assess NO activity. We observed that increased nitrites concentrations in untreated and relapsing patients associated with tumor development. Moreover, nitrites levels were similar in remissive, cured and healthy individuals. Altogether, our results suggest that NO might be an interesting blood biomarker to monitor tumor growth in NPC patients.
Collapse
Affiliation(s)
- Mehdi Bourouba
- USTHB, Laboratory of Cellular and Molecular Biology (LBCM), Team Cytokines and Nitric oxide synthases, Immunity and pathogeny, Bab-Ezzouar, Algiers, Algeria.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Mojic M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Stosic-Grujicic S, Stankovic M, Mangano K, Travali S, Donia M, Fagone P, Zocca MB, Al-Abed Y, McCubrey JA, Nicoletti F. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. Mol Pharmacol 2012; 82:700-10. [PMID: 22798453 DOI: 10.1124/mol.112.077842] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
We have examined the influence of the nitric oxide (NO)-modified anti-inflammatory drug (S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid (VGX-1027) named GIT-27NO or the NO-modified antiviral drug saquinavir (Saq) named Saq-NO on two colon cancer cell lines, mouse CT26CL25 and human HCT116. The effects of the drugs on cell viability, apoptosis, proliferation, and metastatic potential were analyzed. The release of NO and oxygen and nitrogen species was also determined. The efficacy of the drugs was evaluated in vivo in BALB/c mice injected with CT26CL25 cells. Both agents suppressed the growth of colon cancer cells in vitro and reduced tumor volume in syngeneic BALB/c mice. However, their mechanisms of action were different because GIT-27NO released larger amounts of nitrite than Saq-NO in cell cultures and its antitumor action depended on the intracellular NO release inside the cells. On the contrary, Saq-NO released barely detectable amounts of NO and its antitumor action was NO-independent. In fact, cotreatment with an NO-peroxynitrite scavenger revealed that GIT-27NO but not Saq-NO acts through peroxynitrite-mediated cell destruction. At the cellular level, GIT-27NO prevalently induced proapoptotic signals followed by caspase-dependent apoptosis. In contrast, Saq-NO blocked cell proliferation, changed the adhesive, migratory, and invasive properties of the cells, and decreased metastatic potential in vivo. In conclusion, differences in NO release and oxidative stress generation between GIT-27NO and Saq-NO resulted in different mechanisms that caused cell death.
Collapse
Affiliation(s)
- Marija Mojic
- Department of Immunology, Institute for Biological Research "Sinisa Stankovic", Belgrade University, Belgrade, Serbia
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishill L, Boring D, Crowell JA, Kashfi K. Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents. Bioorg Med Chem Lett 2011; 21:7146-50. [PMID: 22001089 DOI: 10.1016/j.bmcl.2011.09.075] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2011] [Revised: 09/15/2011] [Accepted: 09/19/2011] [Indexed: 12/22/2022]
Abstract
Several acetyl-protected hydroxybenzyl diethyl phosphates (EHBPs) that are capable of forming quinone methide intermediates were synthesized and their cell growth inhibitory properties were evaluated in four different human cancer cell lines. Compounds 1, 1a, and 1b, corresponding to (4-acetyloxybenzyl diethylphosphate), (3-methyl-4-acetyloxybenzyl diethylphosphate), and (3-chloro-4-acetyloxybenzyl diethylphosphate), were significantly more potent than compounds 2 and 3, (2-acetyloxybenzyl diethylphosphate) and (3-acetyloxybenzyl diethylphosphate), respectively. Using HT-29 human colon cancer cells, compounds 1 and 3 increased apoptosis, inhibited proliferation, and caused a G(2)/M block in the cell cycle. Our data suggest that these compounds merit further investigation as potential anti-cancer agents.
Collapse
Affiliation(s)
- Ravinder Kodela
- Department of Physiology and Pharmacology, City University of New York Medical School, New York, NY 10031, USA
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Vittorino E, Sciortino MT, Siracusano G, Sortino S. Light-Activated Release of Nitric Oxide with Fluorescence Reporting in Living Cells. ChemMedChem 2011; 6:1551-4, 1534. [DOI: 10.1002/cmdc.201100198] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2011] [Indexed: 11/11/2022]
|
13
|
Mijatovic S, Maksimovic-Ivanic D, Mojic M, Timotijevic G, Miljkovic D, Mangano K, Donia M, Di Cataldo A, Al-Abed Y, Cheng KF, Stosic-Grujicic S, Nicoletti F. Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. J Cell Physiol 2011; 226:1803-12. [DOI: 10.1002/jcp.22513] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
14
|
Mijatovic SA, Timotijevic GS, Miljkovic DM, Radovic JM, Maksimovic-Ivanic DD, Dekanski DP, Stosic-Grujicic SD. Multiple antimelanoma potential of dry olive leaf extract. Int J Cancer 2011; 128:1955-65. [PMID: 20568104 DOI: 10.1002/ijc.25526] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Various constituents of the olive tree (Olea europaea) have been traditionally used in the treatment of infection, inflammation, prevention of chronic diseases, cardiovascular disorders and cancer. The anticancer potential of dry olive leaf extract (DOLE) represents the net effect of multilevel interactions between different biologically active compounds from the extract, cancer cells and conventional therapy. In this context, it was of primary interest to evaluate the influence of DOLE on progression of the highly malignant, immuno- and chemoresistant type of skin cancer-melanoma. DOLE significantly inhibited proliferation and subsequently restricted clonogenicity of the B16 mouse melanoma cell line in vitro. Moreover, late phase tumor treatment with DOLE significantly reduced tumor volume in a syngeneic strain of mice. DOLE-treated B16 cells were blocked in the G(0) /G(1) phase of the cell cycle, underwent early apoptosis and died by late necrosis. At the molecular level, the dying process started as caspase dependent, but finalized as caspase independent. In concordance, overexpression of antiapoptotic members of the Bcl-2 family, Bcl-2 and Bcl-XL, and diminished expression of their natural antagonists, Bim and p53, were observed. Despite molecular suppression of the proapoptotic process, DOLE successfully promoted cell death mainly through disruption of cell membrane integrity and late caspase-independent fragmentation of genetic material. Taken together, the results of this study indicate that DOLE possesses strong antimelanoma potential. When DOLE was applied in combination with different chemotherapeutics, various outcomes, including synergy and antagonism, were observed. This requires caution in the use of the extract as a supplementary antitumor therapeutic.
Collapse
Affiliation(s)
- Sanja A Mijatovic
- Department of Immunology, Institute for Biological Research, Belgrade University, Belgrade, Serbia.
| | | | | | | | | | | | | |
Collapse
|
15
|
Ratanatawanate C, Chyao A, Balkus KJ. S-Nitrosocysteine-Decorated PbS QDs/TiO2 Nanotubes for Enhanced Production of Singlet Oxygen. J Am Chem Soc 2011; 133:3492-7. [DOI: 10.1021/ja109328a] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- Chalita Ratanatawanate
- Department of Chemistry and the Alan G. MacDiarmid NanoTech Institute, The University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080-3021, United States
| | - Amy Chyao
- Department of Chemistry and the Alan G. MacDiarmid NanoTech Institute, The University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080-3021, United States
| | - Kenneth J. Balkus
- Department of Chemistry and the Alan G. MacDiarmid NanoTech Institute, The University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080-3021, United States
| |
Collapse
|
16
|
Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Goswami S, Kodela R, Saavedra JE, Keefer LK, Kashfi K. JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism. Biochem Pharmacol 2010; 80:1641-9. [PMID: 20797387 PMCID: PMC6959133 DOI: 10.1016/j.bcp.2010.08.011] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2010] [Revised: 08/13/2010] [Accepted: 08/16/2010] [Indexed: 12/17/2022]
Abstract
β-Catenin is a central player of the Wnt signaling pathway that regulates cell-cell adhesion and may promote leukemia cell proliferation. We examined whether JS-K, an NO-donating prodrug, modulates the Wnt/β-catenin/TCF-4 signaling pathway in Jurkat T-Acute Lymphoblastic Leukemia cells. JS-K inhibited Jurkat T cell growth in a concentration and time-dependent manner. The IC(50)s for cell growth inhibition were 14±0.7 and 9±1.2μM at 24 and 48h, respectively. Treatment of the cells with JS-K for 24h, caused a dose-dependent increase in apoptosis from 16±3.3% at 10μM to 74.8±2% at 100μM and a decrease in proliferation. This growth inhibition was also due, in part, to alterations in the different phases of the cell cycle. JS-K exhibited a dose-dependent cytotoxicity as measured by LDH release at 24h. However, between 2 and 8h, LDH release was less than 20% for any indicated JS-K concentration. The β-catenin/TCF-4 transcriptional inhibitory activity was reduced by 32±8, 63±5, and 93±2% at 2, 10, and 25μM JS-K, respectively, based on luciferase reporter assays. JS-K reduced nuclear β-catenin and cyclin D1 protein levels, but cytosolic β-catenin expression did not change. Based on a time-course assay of S-nitrosylation of proteins by a biotin switch assay, S-nitrsolyation of nuclear β-catenin was determined to precede its degradation. A comparison of the S-nitrosylated nuclear β-catenin to the total nuclear β-catenin showed that β-catenin protein levels were degraded at 24h, while S-nitrosylation of β-catenin occurred earlier at 0-6h. The NO scavenger PTIO abrogated the JS-K mediated degradation of β-catenin demonstrating the need for NO.
Collapse
Affiliation(s)
- Niharika Nath
- Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
- Department of Life Sciences, New York Institute of Technology, New York, NY, United States
| | - Mitali Chattopadhyay
- Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
| | - Liliya Pospishil
- Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
| | - Lucyna Z. Cieciura
- Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
| | - Satindra Goswami
- Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
| | - Ravinder Kodela
- Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
| | - Joseph E. Saavedra
- Basic Research Program, SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, MD, United States
| | - Larry K. Keefer
- Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, Frederick, MD, United States
| | - Khosrow Kashfi
- Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
| |
Collapse
|
17
|
The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. Eur J Pharmacol 2009; 615:228-33. [DOI: 10.1016/j.ejphar.2009.04.069] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2009] [Revised: 04/24/2009] [Accepted: 04/29/2009] [Indexed: 11/20/2022]
|